Navigation Links
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies

SAN MARINO, Calif., Nov. 20 /PRNewswire/ -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Rexin-G i.v. over a period up to 9 months. Analysis of safety and efficacy data showed no major toxicity, while documenting significant control of tumor growth.

Analysis of efficacy in 42 patients with bone and soft tissue sarcoma showed a dose-response relationship between overall survival and Rexin-G which was highly significant. A confirmatory Phase II study in 17 osteosarcoma patients showed a median overall survival greater than seven months; that is, after failing standard chemotherapies. Two patients are disease-free greater than 6 months after surgical resection of residual tumors and Rexin-G given as both neoadjuvant and adjuvant monotherapy. These studies indicate that (i) intravenous Rexin-G is safe and well-tolerated, and (ii) Rexin-G controls tumor growth and improves survival in a dose-dependent manner in patients with chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about Rexin-G and Epeius Biotechnologies' pipeline of proprietary compounds currently available for clinical development, please visit us at .

*(LOGO 72dpi:

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R).

SOURCE Epeius Biotechnologies
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
2. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
3. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
4. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
5. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
6. New Insight Into the Controls on a Go-To Enzyme
7. Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
8. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
9. Chipscreen Biosciences and HUYA Bioscience Intl Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000, New HDAC Inhibitor for Cancer
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
Post Your Comments:
(Date:10/12/2015)... A new computer program that analyzes functional brain MRIs ... develop effective language skills within two years of cochlear ... Brain and Behavior . ... 12 online edition, researchers at Cincinnati Children,s Hospital Medical ... of the brain respond to auditory stimulus tests that ...
(Date:10/12/2015)... 2015  To help address the growing opioid epidemic ... Surgeons (AAOS) Board of Directors is calling for ... patient education; the tracking of opioid prescription use; research ... effective opioid abuse treatment programs. David Ring ... Safety Committee. "The new , AAOS Information Statement on ...
(Date:10/12/2015)... , Oct. 12, 2015  Today, Divurgent is honored to ... Services. As a former CIO, Paul brings 15 years of ... understand or sympathize with today,s CIOs, he is one. The ... challenges Paul has faced, and his new role with Divurgent ... technology efficiencies across an organization. ...
Breaking Medicine Technology:
(Date:10/13/2015)... Laguna Hills, CA (PRWEB) , ... October 13, ... ... document management and workflow solutions, announced today their Title Sponsorship of Synergy 2015. ... 15th in Henderson, NV at Green Valley Ranch and will unite customers, partners, ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... Illinois with more than 59,000 emergency department visits per year, today announced the ... T-System, to help improve clinical, operational and financial outcomes. , In ...
(Date:10/13/2015)... ... October 13, 2015 , ... California ... of Nursing. Dr. McLeod—who earned her Doctor of Nursing Practice from the renowned ... has spanned four decades. , Dr. McLeod’s long and successful nursing practice included ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... According to ... Rose suffered an orbital fracture when a teammate accidentally elbowed him in the left ... Rose's recent eye injury is just one of a series of setbacks, including a ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... With Fall ... heat styling tool for this month’s Facebook Hair Styler Contest. , Enter to win! ... Contest Image Answering: What Is Your Favorite Hair Style? , 3. Follow us on ...
Breaking Medicine News(10 mins):